Indoprofen

Summary

Indoprofen (CHEMBL15870) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AE10); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AE10
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 281.3 Da · C17H15NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL15870
Name	Indoprofen
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3718
ChEBI	CHEBI:76162
ATC	M01AE10
Molecular formula	C17H15NO3
Molecular weight	281.3
InChIKey	RJMIEHBSYVWVIN-UHFFFAOYSA-N

SMILES: CC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O

IUPAC name: 2-[4-(3-oxo-1H-isoindol-2-yl)phenyl]propanoic acid

ChEBI definition: A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor.

Also known as: Bor-ind, Flosin, Flosint, Indoprofen, Indoprofene, Indoprofeno, Isindone, K 4277, K-4277, NSC-757065, Praxis, Reumofene

Patent coverage: 5,634 distinct patent families (22,854 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 22,694 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Pyruvate kinase PKM, Nuclear receptor ROR-gamma, Survival motor neuron protein, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Protein deacetylase HDAC6, D(1A) dopamine receptor, Progesterone receptor, Nuclear factor NF-kappa-B complex, Lysosomal alpha-glucosidase.

Bioactivity

ChEMBL activities: 19 potent at pChembl ≥ 5 of 28 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	7.16	AC50	69.4	nM	CHEMBL_ACT_25174525
NPC1	7.05	Potency	89.1	nM	CHEMBL_ACT_4708580
GAA	6.75	Potency	177.8	nM	CHEMBL_ACT_4989147
GAA	6.75	Potency	177.8	nM	CHEMBL_ACT_5037929
RAB9A	6.5	Potency	316.2	nM	CHEMBL_ACT_3846011
HDAC6	6.29	IC50	512.7	nM	CHEMBL_ACT_23141005
DRD1	6.29	AC50	510	nM	CHEMBL_ACT_25180648
P02692	5.9	Ki	1270	nM	CHEMBL_ACT_2445234
SMN1	5.9	Potency	1259	nM	CHEMBL_ACT_3891170
NFKB1	5.82	EC50	1518	nM	CHEMBL_ACT_3698187
P51450	5.75	Potency	1778	nM	CHEMBL_ACT_4782973
HTT	5.7	Potency	1995	nM	CHEMBL_ACT_4855699
HTT	5.65	Potency	2239	nM	CHEMBL_ACT_4835362
P51450	5.4	Potency	3981	nM	CHEMBL_ACT_4095723
P51450	5.3	Potency	5012	nM	CHEMBL_ACT_4807106
SMN1	5.2	Potency	6310	nM	CHEMBL_ACT_3878124
P51450	5.05	Potency	8912	nM	CHEMBL_ACT_4087735
TP53	5	Potency	10000	nM	CHEMBL_ACT_4830796
TP53	5	Potency	10000	nM	CHEMBL_ACT_4870077

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06314464	Not specified	UNKNOWN	Portable Mixed Reality-based Platform for Assessment of Progress in Multisensory Rehabilitation Strategies Post-TBI

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).